Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy

详细信息    查看全文

• 作者：Yan-feng Li^a ; Fang-fang Ge^a ; Yong Zhang^a ; Hui You^b ; Zhen-xin Zhang^a ; ^{wuzhangzhenxin@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：cerebral amyloid angiopathy ; Alzheimer's disease ; cerebrospinal fluid biomarker
• 刊名：Chinese Medical Sciences Journal
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：30
• 期：3
• 页码：170-173

文摘

To study the changes of biomarkers in cerebrospinal fluid (CSF) in cerebral amyloid angiopathy (CAA) dementia and Alzheimer's disease.

Methods

Levels of amyloid protein β (Aβ₄₂, Aβ₄₀) and phosphorylated Tau-protein (P-tau) in CSF and ratio of Aβ₄₂/Aβ₄₀ were tested in 5 cases with CAA dementia and 20 cases with Alzheimer's disease collected at Peking Union Medical College Hospital from December 2001 to March 2011.

Results

The levels of Aβ₄₂, Aβ₄₀, and P-tau in CSF and ratio of Aβ₄₂/Aβ₄₀ were (660.4±265.2) ng/L, (7111.0±1033.4) ng/L, (71.8±51.5) ng/L, and 0.077±0.033, respectively in CAA dementia and (663.6±365.6) ng/L, (5115.0±2931.1) ng/L, (47.7±38.8) ng/L, and 0.192±0.140, respectively in Alzheimer's disease patients. There were no statistically significant differences between CAA dementia and Alzheimer's disease in terms of these CSF biomarkers (all P>0.05).

Conclusion

Measurements of CSF biomarkers may not be helpful in differential diagnosis of CAA and Alzheimer's disease.